

**OSPEMIFENE film-coated tablets (Senshio<sup>®</sup> ▼)**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of OSPEMIFENE film-coated tablets (Senshio<sup>®</sup> ▼) for the treatment of vulvar and vaginal atrophy in post-menopausal women**

**GREY**

Ospemifene (Senshio<sup>®</sup> ▼) is an oral selective oestrogen receptor modulator which is licensed for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.<sup>1</sup>

An in-year application has been received and this recommendation has been prioritised for review by the New Medicines Subgroup.

In the meantime, prescribers should continue to follow national guidance and local formulary choices for the treatment of vulvar and vaginal atrophy in post-menopausal women.

- > NICE NG23 (November 2015) – [Menopause: diagnosis and management](#)
- > Clinical Knowledge Summaries (March 2017) – [Menopause](#)
- > Pan Mersey Formulary - [Treatment of vaginal and vulval conditions](#)

**References**

1. Shionogi Limited. Summary of Product Characteristics; Senshio 60mg film-coated tablets, 20 August 2018. Accessed 20 December 2018 at: <https://www.medicines.org.uk/emc/product/9417>

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.